4.60

0.97% -0.04

After Hours: 4.62 0.02 +0.43%

Capricor Therapeutics Inc (CAPR)

Overview News Price History Option Chain Financials Why CAPR Down? Discussions Forecast Stock Split

Capricor Therapeutics Inc stock is traded at $4.60, with a volume of 3.48M. It is down -0.97% in the last 24 hours and down -25.89% over the past month. Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Previous Close:

$4.64

Open:

$4.45

24h Volume:

3.48M

Relative Volume:

2.36

Market Cap:

$210.30M

Revenue:

$27.10M

Net Income/Loss:

$-24.31M

P/E Ratio:

-5.5422

EPS:

-0.83

Net Cash Flow:

$-33.33M

1W Performance:

-18.53%

1M Performance:

-25.89%

6M Performance:

-55.17%

1Y Performance:

-75.58%

1-Day Range:

$4.30

$4.84

1-Week Range:

$4.30

$6.01

52-Week Range:

$4.30

$20.75

Capricor Therapeutics Inc Stock (CAPR) Company Profile

Name

Capricor Therapeutics Inc

Sector

Healthcare (1142)

Industry

Biotechnology (635)

Phone

(310) 358-3200

Address

10865 ROAD TO THE CURE, SAN DIEGO, CA

Employee

160

Twitter

@Capricor

Next Earnings Date

2025-03-19

Latest SEC Filings

CAPR's Discussions on Twitter

Compare CAPR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CAPR Capricor Therapeutics Inc	4.60	212.13M	27.10M	-24.31M	-33.33M	-0.83
VRTX Vertex Pharmaceuticals Inc	429.82	107.58B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	787.32	80.03B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	429.80	57.37B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	917.93	55.83B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	209.02	44.13B	447.02M	-1.18B	-906.14M	-6.1812

Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-30-25	Initiated	Alliance Global Partners	Buy
Jun-26-25	Initiated	B. Riley Securities	Buy
May-20-25	Initiated	Roth Capital	Buy
Oct-21-24	Initiated	Piper Sandler	Overweight
May-17-24	Initiated	Oppenheimer	Outperform
Jan-05-24	Initiated	Cantor Fitzgerald	Overweight
Oct-26-22	Initiated	Ladenburg Thalmann	Buy
Dec-26-18	Downgrade	Maxim Group	Buy → Hold
Jan-26-18	Reiterated	H.C. Wainwright	Buy
Sep-15-17	Reiterated	H.C. Wainwright	Buy
Feb-13-17	Resumed	Rodman & Renshaw	Buy
Jul-06-16	Resumed	H.C. Wainwright	Buy
Jun-15-16	Initiated	ROTH Capital	Buy

View All

Capricor Therapeutics Inc Stock (CAPR) Latest News

Nov 24, 2025

‘Pharma Bro’ Martin Shkreli Goes Short On Capricor Therapeutics – Stock Tumbles 17% - Stocktwits

Nov 24, 2025

Capricor Therapeutics (CAPR) Stock Is Sliding Today: Should Retail Investors Be Worried? - inkl

Nov 24, 2025

Capricor Therapeutics stock tumbles after Martin Shkreli short call - Investing.com

Nov 24, 2025

Capricor Therapeutics stock tumbles after Martin Shkreli short call By Investing.com - Investing.com Canada

Nov 24, 2025

Capricor presents scalable framework for loading therapeutics into exosomes - Investing.com India

Nov 24, 2025

Capricor Therapeutics (CAPR) Showcases Scalable Exosome Loading Framework - GuruFocus

Nov 24, 2025

Capricor Therapeutics Presents New Data Demonstrating a - GlobeNewswire

Nov 24, 2025

Nov 22, 2025

Precision Trading with Capricor Therapeutics Inc. (CAPR) Risk Zones - news.stocktradersdaily.com

Nov 22, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeuti - The National Law Review

Nov 22, 2025

Nov 20, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Nov 20, 2025

Can Capricor Therapeutics Inc. stock attract ESG capital inflowsCEO Change & Precise Entry and Exit Recommendations - newser.com

Nov 20, 2025

How high can Capricor Therapeutics Inc. stock go2025 Big Picture & Technical Buy Zone Confirmation - newser.com

Nov 20, 2025

Is Capricor Therapeutics Inc. (4LN2) stock undervalued by metricsPortfolio Profit Report & Safe Capital Growth Tips - newser.com

Nov 20, 2025

Nov 19, 2025

Will Capricor Therapeutics Inc. price bounce be sustainableRecession Risk & Fast Exit/Entry Strategy Plans - newser.com

Nov 19, 2025

Capricor Therapeutics Inc.’s volatility index tracking explainedTrade Exit Summary & Daily Technical Stock Forecast Reports - newser.com

Nov 19, 2025

How big funds are accumulating Capricor Therapeutics Inc. (4LN2) stockOil Prices & Short-Term High Return Ideas - newser.com

Nov 19, 2025

How Capricor Therapeutics Inc. stock reacts to oil pricesShare Buyback & Capital Efficient Trading Techniques - newser.com

Nov 19, 2025

What valuation multiples suggest for Capricor Therapeutics Inc. stockRisk Management & Daily Growth Stock Tips - newser.com

Nov 19, 2025

Is Capricor Therapeutics Inc. (4LN2) stock a momentum leader2025 Major Catalysts & Weekly Sector Rotation Insights - newser.com

Nov 19, 2025

Will Capricor Therapeutics Inc. stock benefit from upcoming earnings reports2025 Retail Activity & High Return Stock Watch Alerts - newser.com

Nov 19, 2025